Remedy Plan, Inc.
Remedy Plan Therapeutics is dedicated to developing innovative cancer therapeutics, focusing on NAMPT inhibition. The company leverages proprietary drug screening platforms and collaborates with leading scientists to advance its pipeline of drug candidates. Their mission is to improve patient outcomes through scientific breakthroughs and to make research more sustainable and accessible.
Industries
Nr. of Employees
small (1-50)
Products
First-in-class hyperbolic NAMPT inhibitor (oncology clinical candidate)
A small-molecule NAMPT inhibitor developed to avoid on-target toxicities associated with prior NAMPT inhibitors; advanced into IND-enabling studies and Phase I clinical trials for oncology.
NAMPT-targeted preclinical candidates for autoimmune and metabolic indications
Preclinical small-molecule NAMPT-targeting programs aimed at autoimmune diseases and obesity, discovered via the company's screening and optimization workflows.
Discovery-stage candidates addressing additional oncology targets
Discovery-stage small-molecule programs targeting additional pathways relevant to cancer stem cell biology and tumor progression.
First-in-class hyperbolic NAMPT inhibitor (oncology clinical candidate)
A small-molecule NAMPT inhibitor developed to avoid on-target toxicities associated with prior NAMPT inhibitors; advanced into IND-enabling studies and Phase I clinical trials for oncology.
NAMPT-targeted preclinical candidates for autoimmune and metabolic indications
Preclinical small-molecule NAMPT-targeting programs aimed at autoimmune diseases and obesity, discovered via the company's screening and optimization workflows.
Discovery-stage candidates addressing additional oncology targets
Discovery-stage small-molecule programs targeting additional pathways relevant to cancer stem cell biology and tumor progression.
Expertise Areas
- Small-molecule drug discovery
- NAMPT-targeted therapeutic development
- High-throughput screening and hit discovery
- Medicinal chemistry and SAR-driven optimization
Key Technologies
- High-throughput screening (HTS)
- Automated liquid handling and acoustic dispensing
- Cell-based assays
- qPCR / quantitative gene expression
News & Updates
Remedy Plan Therapeutics won $5,000 at the Maryland Tech Council's inaugural Bio+Tech18 pitch competition, supporting their development of cancer stem cell targeting drugs.
Remedy Plan has begun dosing in a Phase 1 clinical trial for RPT1G, a first-in-class hyperbolic NAMPT inhibitor, aiming to evaluate its safety profile.
The company presented preclinical data demonstrating synergy of RPT1G with BCL-2 family inhibitors in AML at the 2024 ASH Annual Meeting.
Remedy Plan announced its presentation at the 66th American Society of Hematology (ASH) Annual Meeting.
The company presented its novel NAMPT inhibitor during a podium presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
Remedy Plan Therapeutics won the inaugural Bio+Tech18 pitch competition, securing funding to accelerate drug development.
Remedy Plan Therapeutics won $5,000 at the Maryland Tech Council's inaugural Bio+Tech18 pitch competition, supporting their development of cancer stem cell targeting drugs.
Remedy Plan has begun dosing in a Phase 1 clinical trial for RPT1G, a first-in-class hyperbolic NAMPT inhibitor, aiming to evaluate its safety profile.
The company presented preclinical data demonstrating synergy of RPT1G with BCL-2 family inhibitors in AML at the 2024 ASH Annual Meeting.
Remedy Plan announced its presentation at the 66th American Society of Hematology (ASH) Annual Meeting.
The company presented its novel NAMPT inhibitor during a podium presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
Remedy Plan Therapeutics won the inaugural Bio+Tech18 pitch competition, securing funding to accelerate drug development.